Breaking News Instant updates and real-time market news.

EWT

Shares MSCI Taiwan Index Fund

$37.42

(0.00%)

, IPHI

Inphi

$35.43

(0.00%)

09:40
08/08/17
08/08
09:40
08/08/17
09:40

Unusually active option classes on open August 8th

Unusual total active option classes on open include: iShares Taiwan (EWT), Inphi (IPHI), Michael Kors (KORS), Twilio (TWLO), Rio Tinto (RIO), Valeant (VRX), Mondelez (MDLZ), J C Penney (JCP), First Solar (FSLR), and iShares iBoxx Dollar High Yield Corporate Bond Fund (HYG).

EWT

Shares MSCI Taiwan Index Fund

$37.42

(0.00%)

IPHI

Inphi

$35.43

(0.00%)

KORS

Michael Kors

$37.23

(0.00%)

TWLO

Twilio

$30.53

(0.00%)

RIO

Rio Tinto

$47.85

(0.00%)

VRX

Valeant

$15.37

(0.00%)

MDLZ

Mondelez

$43.99

0.51 (1.17%)

JCP

J.C. Penney

$5.39

(0.00%)

FSLR

First Solar

$48.57

0.59 (1.23%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.46

(0.00%)

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 09

    Aug

  • 10

    Aug

  • 10

    Aug

  • 11

    Aug

  • 11

    Aug

  • 24

    Aug

  • 29

    Aug

  • 25

    Sep

EWT Shares MSCI Taiwan Index Fund
$37.42

(0.00%)

IPHI Inphi
$35.43

(0.00%)

05/03/17
NEED
05/03/17
NO CHANGE
Target $46
NEED
Strong Buy
Inphi price target lowered to $46 from $55 at Needham
Needham analyst N. Quinn Bolton lowered his price target for Inphi to $46 from $55 after the company reported in-line Q1 results but guided Q2 well below expectations reflecting an inventory buildup in the China Long Haul and Metro segment. As the analyst believes this is just a one or two quarter inventory correction, he encourages investors to buy the stock on weakness ahead of the anticipated recovery in 2H17. He reiterates a Strong Buy rating on the shares.
08/08/17
ROTH
08/08/17
NO CHANGE
Target $44
ROTH
Buy
Inphi price target lowered to $44 from $51.70 at Roth Capital
Roth Capital analyst Roth Capital lowered his price target for Inphi to $44 from $51.70 on valuation as well-known market challenges constrict guidance, but long-term prospects remain. The analyst reiterates a Buy rating on the shares.
05/03/17
CHLM
05/03/17
NO CHANGE
Target $49
CHLM
Buy
Inphi price target lowered to $49 from $59 at Craig-Hallum
Craig-Hallum analyst Richard Shannon lowered his price target for Inphi to $49 from $59 as the company's Q2 guidance driven by severe inventory burn in was worse than expected. The analyst, however, argues that Colorz is ramping ahead of plan and lower Q2 gross margin guide is not a concern, and says he is a buyer on big dips. He reiterates a Buy rating on the shares.
08/08/17
CHLM
08/08/17
NO CHANGE
Target $44
CHLM
Buy
Inphi price target lowered to $44 from $49 at Craig-Hallum
Craig-Hallum analyst Richard Shannon lowered his price target for Inphi to $44 from $49, while noting that the company's soft Q3 guide was not a surprise based on reports last week, as the inventory situation in China remains cloudy at best. The analyst reiterates a Buy rating on the shares.
KORS Michael Kors
$37.23

(0.00%)

06/01/17
UBSW
06/01/17
NO CHANGE
Target $55
UBSW
Buy
Michael Kors store closures positive for Coach, says UBS
UBS analyst Michael Binetti noted Michael Kors (KORS) announced plans to start closing stores and it is assumed they will be skewed to North America. The analyst believes Michael Kors has been the number one competitive pressure for Coach (COH) over the past five years so its decision to close stores now relieves the company of its number one headwind. He now believes Coach is well positioned as a market share gainer. Binetti reiterated his Buy rating and $55 price target on Coach shares.
07/10/17
MKMP
07/10/17
INITIATION
Target $26
MKMP
Sell
Michael Kors initiated with a Sell at MKM Partners
MKM Partners initiated Michael Kors with a Sell and a $26 price target.
06/01/17
ADAM
06/01/17
NO CHANGE
Target $33
ADAM
Hold
Michael Kors guidance underscores broader challenges ahead, says Canaccord
Canaccord analyst Camilo Lyon noted Michael Kors beat Q4 estimates but said its weaker guidance underscores the broader challenges ahead for the company. Lyon said the company is finally taking aggressive course-correcting action to enhance the brand's position along with cost-savings. The analyst said the macro challenges in the U.S. and Europe remain and there is significant execution risk at hand. Lyon maintained his Hold rating and lowered his price target to $33 from $38 on Michael Kors shares.
07/31/17
07/31/17
DOWNGRADE
Target $45

Hold
Coach downgraded to Hold from Buy at Jefferies
Jefferies analyst Randal Konik downgraded Coach (COH) to Hold citing valuation. The company's recovery is playing out, "but everyone knows it," Konik tells investors in a research note. The analyst lowered his price target for Coach shares to $45 from $53 and recommends buying shares of Michael Kors (KORS), where he feels the valuation and expectations are lower.
TWLO Twilio
$30.53

(0.00%)

08/08/17
JPMS
08/08/17
NO CHANGE
Target $40
JPMS
Overweight
Twilio price target raised to $40 from $33 at JPMorgan
JPMorgan analyst Mark Murphy raised his price target for Twilio shares to $40 following the company's Q2 results. The core ex-Uber business is stronger than expected while enterprise wins are bringing diversification, Murphy tells investors in a post-earnings research note. He keeps an Overweight rating on the shares.
08/08/17
MUFG
08/08/17
UPGRADE
Target $35
MUFG
Overweight
Twilio upgraded to Overweight from Neutral at MUFG
MUFG analyst Stephen Bersey upgraded Twilio to Overweight and raised his price target for the shares to $35 from $23. The company last night reported an "impressive "quarter, even when factoring in lost revenue from Uber, the analyst contends. He believes Twilio's new products look promising.
07/10/17
BARD
07/10/17
INITIATION
Target $35
BARD
Outperform
Twilio initiated with an Outperform at Baird
Baird analyst William Power initiated Twilio with an Outperform and a $35 price target.
08/08/17
ADAM
08/08/17
NO CHANGE
Target $38
ADAM
Buy
Twilio shares will be range bound with upward bias, says Canaccord
Canaccord analyst Richard Davis said Twilio posted excellent Q2 results and he expects the shares to trade in a range between $30-$40 with an upward bias over the next few months as investors conclude that 2018 estimates are a floor level with a bit of upside. Davis reiterated his Buy rating on Twilio shares.
RIO Rio Tinto
$47.85

(0.00%)

04/20/17
SBSH
04/20/17
UPGRADE
SBSH
Buy
Rio Tinto upgraded to Buy from Neutral at Citi
Citi analyst Clarke Wilkins upgraded Rio Tinto to Buy citing the recent pullback in the shares. The analyst sees further upside to the announced capital management program and keeps an A$70 price target for the shares.
04/20/17
EXAN
04/20/17
UPGRADE
EXAN
Outperform
Rio Tinto upgraded to Outperform from Neutral at Exane BNP Paribas
05/17/17
RBCM
05/17/17
UPGRADE
RBCM
Top Pick
Rio Tinto upgraded to Top Pick from Outperform at RBC Capital
RBC Capital analyst Tyler Broda upgraded Rio Tinto to Top Pick following the recent pullback in shares. The analyst believes the market is taking too negative a view on the medium-term iron ore market and not the low cost, high free cash flow story.
04/07/17
LYON
04/07/17
UPGRADE
LYON
Buy
Rio Tinto upgraded to Buy from Outperform at CLSA
VRX Valeant
$15.37

(0.00%)

07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.
MDLZ Mondelez
$43.99

0.51 (1.17%)

08/03/17
WELS
08/03/17
NO CHANGE
WELS
Mondelez new CEO 'unconventional' but can 'inject fresh ideas,' says Wells Fargo
After Mondolez announced that its CEO would resign and named Dirk Van de Put as her successor, Wells Fargo calls the choice "unconventional." However, the firm thinks that, as an outsider, he will be able to "inject fresh ideas." Wells keeps an Outperform rating on the shares.
07/25/17
07/25/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mondelez (MDLZ) upgraded to Overweight from Neutral at Piper Jaffray with analyst Michael Lavery saying favorable sugar and cocoa costs provide a boost to margins. 2. Big Lots (BIG) upgraded to Buy from Hold at Deutsche Bank analyst Paul Trussell saying the current valuation is "compelling" given the disconnect between the company's "impressive" operating profit growth and multiple. 3. Werner (WERN) upgraded to Neutral from Underperform at BofA/Merrill with analyst Ken Hoexter saying truckload utilization and rates are turning positive. 4. Atlassian (TEAM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Sanjit Singh saying has increased confidence in expansion trends of the user base and said there are clear signs of pricing power, supporting 30% topline growth and 40% free cash flow CAGR over the next 3 years. 5. DSW (DSW) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the shares offer an "intriguing non-apparel value play." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/17
PIPR
07/25/17
UPGRADE
Target $49
PIPR
Overweight
Mondelez upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery upgraded Mondelez to Overweight and raised his price target for the shares to $49 from $48. Favorable sugar and cocoa costs provide a boost to margins, Lavery tells investors in a research note. The analyst expects the company's cash build will be applied to buybacks.
06/19/17
FBCO
06/19/17
NO CHANGE
FBCO
Hershey buy of Nestle assets could be type of 'poison pill,' says Credit Suisse
Credit Suisse analyst Robert Moskow analyzed several scenarios after Nestle's (NSRGY) recent announcement of a strategic review of its U.S. confectionery business. Buying Nestle candy would double Mondelez's (MDLZ) U.S. market share to 10%, but Moskow wonders if such a deal could compromise Mondelez' ability to eventually buy Hershey (HSY) at a later date. As for the latter, Hershey would generate "massive" synergies of 9% of sales and the deal could work as a type of "poison pill" to deter a bid from Mondelez or Kraft Heinz (KHC), said Moskow. However, he doesn't think Hershey would want to buy an asset that would dilute its topline growth rate at this point. He added that he sees "little to no chance" of Lindt, the number three in U.S. candy, being interested in Nestle's assets.
JCP J.C. Penney
$5.39

(0.00%)

05/15/17
05/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Adam Jonas saying the bull thesis on Tesla centers around the company becoming the next Amazon (AMZN) or Apple (AAPL), Jonas tells investors in a research note. The analyst, however, questions if the risks of taking on the tech giants is sufficiently discounted in the share price. He expects "much larger and more well capitalized" competitors to unveil strategies that directly address sustainable transport and mobility. 2. J.C. Penney (JCP) was downgraded to Hold from Buy at Deutsche Bank, to Neutral from Outperform at Baird, and to Neutral from Buy at Buckingham. 3. STMicroelectronics (STM) downgraded to Hold from Buy at Stifel. 4. Level 3 (LVLT) and CenturyLink (CTL) were downgraded to Underperform from Market Perform at Raymond James. 5. TSMC (TSM) downgraded to Neutral from Outperform at Credit Suisse with analyst Randy Abrams saying headwinds from excess inventory, slower China smartphones, and Qualcomm (QCOM) shifts to Samsung (SSNLF) could pressure sales and margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/17
GDHS
06/21/17
NO CHANGE
GDHS
Nike-Amazon pact yet another department store headwind, says Gordon Haskett
Gordon Haskett analyst noted the reports of Nike (NKE) nearing a deal to sell directly on Amazon (AMZN), which he said wouldn't impact trends overnight but would represent another headwind for department stores, particularly J.C. Penney (JCP) and Kohl's (KSS), where the brand has a larger penetration than at Macy's (M) and Nordstrom (JWN). He keeps an Accumulate rating on Nordstrom, a Hold rating on Macy's and Reduce rating on both J.C. Penney and Kohl's.
06/26/17
GDHS
06/26/17
UPGRADE
Target $4.5
GDHS
Accumulate
J.C. Penney upgraded to Hold from Reduce at Gordon Haskett
Gordon Haskett analyst Chuck Grom upgraded J.C. Penney to Hold from Reduce with a $4.50 price target.
07/12/17
SBSH
07/12/17
NO CHANGE
Target $5
SBSH
Neutral
J.C. Penney price target raised to $5 from $4.50 at Citi
Citi analyst Paul Lejuez raised his price target for J.C. Penney to $5 from $4.50 after the retailer announced that Q2 sales had "significantly improved" versus Q1. The analyst upped his FY17 earnings per share estimate to 53c from 40c and keeps a Neutral rating on Penny.
FSLR First Solar
$48.57

0.59 (1.23%)

07/26/17
ROTH
07/26/17
NO CHANGE
Target $55
ROTH
Buy
First Solar price target raised to $55 from $40 at Roth Capital
Roth Capital analyst Philip Shen raised his price for First Solar to $55 from $40 as he sees momentum taking the stock higher given Section 201 and the resulting improved economic prospects for the company. The analyst reiterates a Buy rating on the shares.
07/25/17
BOFA
07/25/17
NO CHANGE
BOFA
Solar sector may be bottoming, First Solar best positioned, says BofA/Merrill
BofA/Merrill analyst Krish Sankar believes the Solar sector may have bottomed in Q2 2017 with installs falling about 23% compared to Q2 2016 as last year's rush was driven by fears of an ITC expiration. Sankar believes global demand is set to increase 2% in 2017, followed by mid-to-high single digit growth going forward. His top solar pick heading into earnings is First Solar (FSLR), followed by Buy rated Veeco (VECO) in the energy efficiency/LED space. The analyst remains sidelined, until there is clarity on future sponsors, in SunPower (SPWR) and 8Point3 (CAFD).
07/25/17
COWN
07/25/17
NO CHANGE
Target $52
COWN
Outperform
First Solar expected to report upside to quarter, says Cowen
Cowen analyst Jeffrey Osborne said he expects First Solar to report upside when they report Q2 results. The analyst will also be looking for commentary on its restructuring efforts as well as progress on its transition to Series 6, which he said is the key to its 2018 story. Osborne reiterated his Outperform rating and raised his price target to $52 from $47 on First Solar shares.
07/28/17
COWN
07/28/17
NO CHANGE
Target $57
COWN
Outperform
First Solar price target raised to $57 from $52 at Cowen
Cowen analyst Jeffrey Osborne raised his price target on First Solar to $57 from $52 following Q2 results. The analyst cited the Section 201 ruling that has led to an increase in U.S. prices, which could favor the 300-500MW of remaining Series 4 supply. Long-term earnings power stems from Series 6, which is on track for production in 2018, said Osborne, who reiterated his Outperform rating on First Solar.
HYG iShares iBoxx $ High Yield Corporate Bond
$88.46

(0.00%)

TODAY'S FREE FLY STORIES

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

, PCG

PG&E

$42.98

2.44 (6.02%)

18:17
06/22/18
06/22
18:17
06/22/18
18:17
Hot Stocks
Northwest Natural to sell Gill Ranch Storage to SENSA Holdings »

NW Natural (NWN)…

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

PCG

PG&E

$42.98

2.44 (6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ORLY

O'Reilly Automotive

$285.90

-1.18 (-0.41%)

18:03
06/22/18
06/22
18:03
06/22/18
18:03
Hot Stocks
O'Reilly Automotive's O'Reilly sells 19,250 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$33.15

0.02 (0.06%)

17:46
06/22/18
06/22
17:46
06/22/18
17:46
Hot Stocks
South Jersey Industries announces approval of Elizabethtown Gas purchase »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$15.36

0.12 (0.79%)

17:27
06/22/18
06/22
17:27
06/22/18
17:27
Hot Stocks
AquaVenture extends long-stop date for Ghana plant acquisition to September 30 »

AquaVenture announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Periodicals
Nissan chooses Thailand for hybrid's first export market, Nikkei reports »

Nissan has planned to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.81

-0.0068 (-0.83%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Hot Stocks
Trovagene CEO William Welch resigns, Dr. Thomas Adams named interim CEO »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$3.26

0.005 (0.15%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.49

-0.15 (-0.45%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Hot Stocks
Aecom to compete for $148.5M U.S. Army contract »

AECOM-Baker JV, Bryan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:17
06/22/18
06/22
17:17
06/22/18
17:17
Hot Stocks
Lockheed Martin awarded $175.3M U.S. Navy contract modification »

Lockheed Martin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:16
06/22/18
06/22
17:16
06/22/18
17:16
Hot Stocks
Lockheed Martin awarded $1.12B U.S. Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

, XLU

Utilities SPDR

$50.75

0.36 (0.71%)

17:14
06/22/18
06/22
17:14
06/22/18
17:14
General news
Week ending ETF Scorecard: Utilities and Real Estate advance, Industrials slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

XLU

Utilities SPDR

$50.75

0.36 (0.71%)

IYR

DJ US Real Estate Index Fund

$80.69

0.56 (0.70%)

XLP

Consumer Staples Sector SPDR

$51.62

0.42 (0.82%)

XLY

Consumer Discretionary Sector SPDR

$111.34

-0.15 (-0.13%)

XLB

S&P Select Materials SPDR

$58.49

0.79 (1.37%)

XLF

Financial Select Sector

$27.07

-0.145 (-0.53%)

XLV

Health Care Select Sector SPDR

$84.91

0.35 (0.41%)

XLK

Technology Select Sector SPDR

$70.78

-0.24 (-0.34%)

XLI

Industrial Select Sector SPDR

$72.59

0.22 (0.30%)

GLD

SPDR Gold Trust

$120.33

0.27 (0.22%)

SLV

iShares Silver Trust

$15.49

0.135 (0.88%)

USO

United States Oil Fund

$14.02

0.71 (5.33%)

UNG

United States Natural Gas Fund

$23.87

-0.24 (-1.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.91

-0.015 (-0.02%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$113.99

0.105 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.57

0.06 (0.05%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.11

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.30

0.005 (0.01%)

IWD

iShares Russell 1000 Value

$122.51

0.56 (0.46%)

IWF

iShares Russell 1000 Growth

$146.24

-0.2 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$5.43

0.14 (2.65%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Hot Stocks
Pfenex set to join Russell 2000 Index »

Pfenex announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXE

Bellatrix Exploration

$1.00

-0.0101 (-1.00%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Syndicate
Breaking Syndicate news story on Bellatrix Exploration »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$44.24

0.25 (0.57%)

16:56
06/22/18
06/22
16:56
06/22/18
16:56
Initiation
Logitech initiated  »

Logitech initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.35

0.925 (3.14%)

16:51
06/22/18
06/22
16:51
06/22/18
16:51
Hot Stocks
Breaking Hot Stocks news story on PagSeguro Digital »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

APLS

Apellis

$21.75

-0.2 (-0.91%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Conference/Events
Apellis to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Periodicals
SEC investigates whether companies rounded up earnings, WSJ reports »

The U.S. Securites and…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$38.20

-0.75 (-1.93%)

16:45
06/22/18
06/22
16:45
06/22/18
16:45
Conference/Events
Gentherm to hold a strategic update »

Strategic Update for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTX

MeiraGTx

$11.86

-0.97 (-7.56%)

16:43
06/22/18
06/22
16:43
06/22/18
16:43
Hot Stocks
Breaking Hot Stocks news story on MeiraGTx »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

16:39
06/22/18
06/22
16:39
06/22/18
16:39
Conference/Events
Medtronic to hold an analyst and investor briefing »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

, FOX

21st Century Fox

$48.28

0.31 (0.65%)

16:35
06/22/18
06/22
16:35
06/22/18
16:35
Hot Stocks
21st Century Fox extends CFO John Nallen's employment contract to 2021 »

On June 22, 21st Century…

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$10.97

0.5 (4.78%)

16:34
06/22/18
06/22
16:34
06/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Fennec »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBBP

Strongbridge Biopharma

$6.20

-0.15 (-2.36%)

16:33
06/22/18
06/22
16:33
06/22/18
16:33
Hot Stocks
Breaking Hot Stocks news story on Strongbridge Biopharma »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

16:30
06/22/18
06/22
16:30
06/22/18
16:30
Options
Preliminary option volume of 16.8M today »

Preliminary option volume…

COOL

PolarityTE

$38.91

-0.09 (-0.23%)

16:28
06/22/18
06/22
16:28
06/22/18
16:28
Conference/Events
PolarityTE to hold a meeting »

Management hosts a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.